Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's Disease.

Antioxidants & redox signaling - 10 Jul 2016

Lastres-Becker Isabel, García-Yagüe Angel J, Scannevin Robert H, Casarejos María J, Kügler Sebastian, Rábano Alberto, Cuadrado Antonio

Abstract excerpt

AIMS: This preclinical study was aimed at determining whether pharmacological targeting of transcription factor NRF2, a master controller of many homeostatic genes, might provide a disease-modifying therapy in the animal model of Parkinson's disease (PD) that best reproduces the main hallmark of this pathology, that is, α-synucleinopathy, and associated events, including nigral dopaminergic cell death, oxidative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy
Share to Drug Repositioning

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gliosis

Share to Immunohistochemistry

Share to Neuroprotective Agents

Share to NF-E2-Related Factor 2

Share to Parkinson Disease

Share to Synucleins

Source

Open in PubMed Open full text

Identifiers

PMID: 27009601
DOI: 10.1089/ars.2015.6549
PMCID: PMC4943471

Genes

NQO1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's Disease.PMID 27009601Read ↗

The Emerging Role of Dimethyl Fumarate in Alzheimer’s Disease—A Systematic Review of Available Preclinical StudiesSemantic proximity Read ↗

Activation of transcription factor Nrf2 to counteract mitochondrial dysfunction in Parkinson's diseaseSemantic proximity Read ↗

α-Synuclein pathology in Parkinson disease activates homeostatic NRF2 anti-oxidant responseSemantic proximity Read ↗

Role of the Transcription Factor Nrf2 in Parkinson’s Disease: New InsightsSemantic proximity Read ↗

Activation of Nrf2 Neuroprotective Pathways for Treatment of Parkinson’s Disease: A State of Art ReviewSemantic proximity Read ↗

Dimethyl fumarate alters microglia phenotype and protects neurons against proinflammatory toxic microenvironments.Semantic proximity Read ↗

Pharmacodynamics of Dimethyl Fumarate Are Tissue Specific and Involve NRF2-Dependent and -Independent MechanismsSemantic proximity Read ↗

Repurposing dimethyl fumarate as an antiepileptogenic and disease-modifying treatment for drug-resistant epilepsySemantic proximity Read ↗

α-syn overexpression, NRF2 suppression, and enhanced ferroptosis create a vicious cycle of neuronal loss in Parkinson’s diseaseSemantic proximity Read ↗

Targeting Nrf2-Mediated Gene Transcription by Extremely Potent Synthetic Triterpenoids Attenuate Dopaminergic Neurotoxicity in the MPTP Mouse Model of Parkinson's DiseaseSemantic proximity Read ↗

Nrf2: a modulator of Parkinson’s disease?Semantic proximity Read ↗

Harnessing the Therapeutic Potential of the Nrf2/Bach1 Signaling Pathway in Parkinson’s DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.